Ron Newfield
Pediatric Endocrinology · San Diego, CANPI 1679644421
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,900 of the $27,229 with a category attached, or 80.4%. Neurocrine Biosciences, Inc. accounts for 79.3% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $21,703, more than ten times the $1,884 reported in 2019. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $209.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$22K
- Merck$3K
- Dexcom, Inc.$377
- Tandem Diabetes Care, Inc.$257
- Eton Pharmaceuticals, Inc.$247
- Ipsen Biopharmaceuticals, Inc$247
- plus $2K from 19 others
Across 107 payments — averaging $6267.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$651K
- Merck$10K
- Zealand Pharma A/s$9K
What the payments were for
- Consulting fees$21,90080%
- Travel & lodging$1,5056%
- Food & beverage$3,67613%
- Education$1481%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 28 | $21,582 |
| Merck | 3 | $3,000 |
| Dexcom, Inc. | 17 | $377 |
| Tandem Diabetes Care, Inc. | 8 | $257 |
| Eton Pharmaceuticals, Inc. | 2 | $247 |
| Ipsen Biopharmaceuticals, Inc | 9 | $247 |
| Insulet Corporation | 10 | $219 |
| AbbVie | 9 | $203 |
| Sanofi-aventis U.S. LLC | 1 | $141 |
| Azurity Pharmaceuticals, Inc. | 6 | $116 |
| Novo Nordisk | 4 | $102 |
| Medtronic(2 entities) | 5 | $101 |
| Pfizer | 5 | $89 |
| Arbor Pharmaceuticals, Inc. | 5 | $87 |
| BETA Bionics, Inc. | 3 | $84 |
| Ferring Pharmaceuticals Inc. | 3 | $74 |
| Tolmar, Inc. | 2 | $64 |
| Ascendis Pharma Endocrinology Inc | 2 | $55 |
| AstraZeneca | 2 | $48 |
| Biomarin Pharmaceutical Inc. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Sequel Med Tech, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Companion Medical, Inc. | 1 | $19 |
| Soleno Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRENESSITY$17,196
- JANUVIA$3,000
- Alkindi$149
- TZIELD$141
- t-slim insulin pump$139
How this compares
$27,229 in reported general payments places this provider in the 90th percentile of 168 pediatric endocrinology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colesevelam Hcl | 14 | $5,925 |
| Ezetimibe | 12 | $166 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in San Diego
- Karen KleinSan Diego$195K
- Marcela Vargas TrujilloSan Diego$57K
- Michael GottschalkSan Diego$17K
- Susan PhillipsSan Diego$12K
- Maja MarinkovicSan Diego$5K
- Mary PattersonSan Diego$4K
- Jane KimSan Diego$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Francine KaufmanLos Angeles$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.